NO20072099L - Anvendelse av epotiloner ved behandling av benmetastaser og bentumorer eller kreft - Google Patents

Anvendelse av epotiloner ved behandling av benmetastaser og bentumorer eller kreft

Info

Publication number
NO20072099L
NO20072099L NO20072099A NO20072099A NO20072099L NO 20072099 L NO20072099 L NO 20072099L NO 20072099 A NO20072099 A NO 20072099A NO 20072099 A NO20072099 A NO 20072099A NO 20072099 L NO20072099 L NO 20072099L
Authority
NO
Norway
Prior art keywords
bone
treatment
cancer
epothilones
tumors
Prior art date
Application number
NO20072099A
Other languages
English (en)
Inventor
Ulrich Klar
Jens Hoffmann
Hubertus Pietsch
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34928830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20072099(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of NO20072099L publication Critical patent/NO20072099L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Den foreliggende oppfinnelse vedrører anvendelsen av epotiloner ved behandlingen av benmetastaser og bentumorer eller benkreftfiormer, nærmere bestemt ved behandling, fiorhindring eller lindring av benmetastaser hos en kreftpasient.
NO20072099A 2004-09-24 2007-04-23 Anvendelse av epotiloner ved behandling av benmetastaser og bentumorer eller kreft NO20072099L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04090377A EP1640004A1 (en) 2004-09-24 2004-09-24 Use of epothilones in the treatment of bone metastases and bone tumors or cancers
PCT/EP2005/010400 WO2006032537A2 (en) 2004-09-24 2005-09-22 Use of epothilones in the treatment of bone metastases and bone tumors or cancers

Publications (1)

Publication Number Publication Date
NO20072099L true NO20072099L (no) 2007-04-23

Family

ID=34928830

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072099A NO20072099L (no) 2004-09-24 2007-04-23 Anvendelse av epotiloner ved behandling av benmetastaser og bentumorer eller kreft

Country Status (21)

Country Link
EP (2) EP1640004A1 (no)
JP (1) JP2008514569A (no)
KR (1) KR20070054214A (no)
CN (1) CN101065126A (no)
AR (1) AR051035A1 (no)
AU (1) AU2005287477A1 (no)
BR (1) BRPI0516080A (no)
CA (1) CA2580215A1 (no)
CR (1) CR9064A (no)
EC (1) ECSP077390A (no)
GT (1) GT200500267A (no)
IL (1) IL181785A0 (no)
MX (1) MX2007003503A (no)
NO (1) NO20072099L (no)
PA (1) PA8646201A1 (no)
PE (1) PE20060695A1 (no)
RU (1) RU2007115162A (no)
TW (1) TW200626150A (no)
UY (1) UY29136A1 (no)
WO (1) WO2006032537A2 (no)
ZA (1) ZA200703306B (no)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1930004A1 (en) * 2006-12-08 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Use of epothilones in the treatment of osteoporosis and related diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
BR9916833A (pt) * 1998-12-22 2001-09-25 Novartis Ag Derivados de epotilona e seu uso como agentes antitumor
AR023792A1 (es) * 1999-04-30 2002-09-04 Bayer Schering Pharma Ag Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos
JP4776843B2 (ja) * 1999-10-01 2011-09-21 イムノゲン インコーポレーティッド 免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
JP2004508810A (ja) * 2000-04-28 2004-03-25 コーサン　バイオサイエンシーズ，　インコーポレイテッド ポリケチドの生成
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
WO2002080846A2 (en) * 2001-04-03 2002-10-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
TWI315982B (en) * 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US7211593B2 (en) * 2002-03-12 2007-05-01 Bristol-Myers Squibb Co. C12-cyano epothilone derivatives
CN1649585A (zh) * 2002-05-01 2005-08-03 诺瓦提斯公司 用于治疗肝脏肿瘤和其它癌症疾病的埃坡霉素衍生物
JP2006510626A (ja) * 2002-12-05 2006-03-30 シエーリング アクチエンゲゼルシャフト 増殖疾患の処理における部位特異的供給のためのエポチロン類似体
GB0305928D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
EP1475105A1 (en) * 2003-05-09 2004-11-10 Schering AG Bone localising radiopharmaceutical and tubulin-interacting compound combinatorial radiotherapy
EP1641449A1 (en) * 2003-06-27 2006-04-05 Novartis AG Cancer treatment with epothilones
CN1870995A (zh) * 2003-09-02 2006-11-29 诺瓦提斯公司 使用埃坡霉素的癌症治疗

Also Published As

Publication number Publication date
AU2005287477A1 (en) 2006-03-30
GT200500267A (es) 2006-06-06
CR9064A (es) 2007-10-01
PE20060695A1 (es) 2006-08-03
PA8646201A1 (es) 2006-11-09
JP2008514569A (ja) 2008-05-08
EP1640004A1 (en) 2006-03-29
MX2007003503A (es) 2007-08-17
BRPI0516080A (pt) 2008-08-19
AR051035A1 (es) 2006-12-13
ZA200703306B (en) 2010-06-30
UY29136A1 (es) 2006-04-28
IL181785A0 (en) 2007-07-04
CA2580215A1 (en) 2006-03-30
WO2006032537A3 (en) 2006-05-04
RU2007115162A (ru) 2008-11-20
EP1809281A2 (en) 2007-07-25
WO2006032537A2 (en) 2006-03-30
CN101065126A (zh) 2007-10-31
ECSP077390A (es) 2007-05-30
KR20070054214A (ko) 2007-05-28
TW200626150A (en) 2006-08-01

Similar Documents

Publication Publication Date Title
EA201690265A3 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
NO20055894L (no) Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer
WO2007013950A3 (en) Combination therapy of her expressing tumors
NO20071585L (no) Ny anvendelse av peptidforbindelser for behandling av benkreftsmerte, kjemoterapi- og nucleosidfremkalt smerte
DE50310516D1 (de) Fredericamycin-derivate
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
EA200800762A1 (ru) Предотвращение гипотензии и стабилизация кровяного давления у гемодиализных пациентов
WO2009044173A3 (en) Methods of treating cancer using notch pathway inhibitors
TW200714604A (en) Substituted heterocycles and the uses thereof
WO2006015035A8 (en) Useful compounds for hpv infection
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
ATE448232T1 (de) Substituierte heterozyklen
GB0121490D0 (en) Ciompounds
NO20055130L (no) Aminocykloheksyleter-forbindelser og deres anvendelse
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
DE602006017980D1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
IL171974A0 (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
NO20080037L (no) Kombinasjon av pyrimidylaminobenzamidforbindelser og imatinib for behandling eller forbyggelse av proliferative sykdommer
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole
NO20065780L (no) Kombinasjonsprodukt omfattende SRC kinase inhibator AZDO 530 og en antiostrogen eller EGFR-TK- inhibitor
GB0121494D0 (en) Compounds
EA200801425A1 (ru) Диазепиноны
NO20060420L (no) 2-aminobenzoylderivater
PL1843771T3 (pl) Zastosowanie pirymidyloaminobenzamidów do leczenia chorób odpowiadających na modulację aktywności kinazy Tie-2

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application